Latest News & Features
Big Pharma
With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe. 2 June 2016
article
Minesoft’s Chemical Explorer helps users to find chemical information in patents issued by multiple authorities. Robert Poolman explains how it works. 2 June 2016
Americas
Jazz Pharmaceuticals, based in Ireland, will buy US company Celator Pharmaceuticals for $1.5 billion in cash. 1 June 2016
Americas
The US Supreme Court has refused to review Cubist Pharmaceuticals’ infringement case over the antibiotic drug Cubicin. 1 June 2016
Americas
Pay-for-delay agreements, otherwise known as reverse settlements, stand at the intersection of intellectual property and competition law, but the clarity hoped for after Actavis has not yet arrived. LSIPR investigates. 1 June 2016
Big Pharma
Despite several major EU rulings on supplementary protection certificates, national IP offices and courts can form differing interpretations, and it seems that a unitary-style SPC right would be hard to create. LSIPR reports. 1 June 2016
Americas
In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review. 31 May 2016
Americas
A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work. 31 May 2016
Americas
Thermo Fisher Scientific has announced that it will buy FEI, an electron microscopy company, for $4.2 billion. 31 May 2016
Americas
Teva and Spectrum Pharmaceuticals have settled a patent dispute over the generic version of Folotyn, a treatment for patients with relapsed or refractory peripheral T-cell lymphoma. 27 May 2016